Janssen Vaccines & Prevention B.V.
Quick facts
| Founded | 2000 |
|---|
Phase 3 pipeline
- Ad26.RSV.preF-based vaccine · Immunology / Infectious Disease
An adenovirus serotype 26 (Ad26)-based vaccine expressing the respiratory syncytial virus (RSV) prefusion F protein to elicit immune responses against RSV infection. - Ad26.ZEBOV 0.8*10^10 (vp) · Immunology / Infectious Disease
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection. - Ad26.ZEBOV 2*10^10 (vp) · Immunology / Infectious Disease
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus. - Al(OH)3 · Immunology
Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity. - MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] · Immunology / Infectious Disease
MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses. - MVA-BN-Filo 5*10^7 Inf. U. · Immunology / Infectious Disease
MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses. - Quadrivalent High-dose Influenza Vaccine · Immunology
This vaccine induces an immune response against multiple influenza strains.
Phase 2 pipeline
Phase 1 pipeline
- Ad26.Filo · Infectious Disease
Ad26.Filo is a viral vector vaccine that targets filoviruses. - Ad26.Mos.HIV · Infectious Disease
HIV vaccine - Ad26.RSV.preF 1*10^11 vp
- Ad26.ZIKV.001 1*10^11 vp
- Ad26.ZIKV.001 5*10^10 vp
- Clade C gp140 plus adjuvant
- gp140 DP High-dose
- gp140 DP Low-dose
- gp140 HIV Bivalent Vaccine
- INFLUENZA G1 mHA
- RSV preF Protein 50 mcg
- Selected Regimen
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: